

Press release for immediate release

## **Genomtec is winning a new partner to commercialize the Genomtec® ID platform in Taiwan (R.O.C.).**

**Wroclaw, Poland – August 10, 2022. - Genomtec S.A. "GMT", a NewConnect-listed MedTech company specialising in the development of advanced technology in the area of point-of-care (POCT) genetic diagnostics has signed up a new Partner for the commercialization of its flagship Genomtec® ID genetic testing platform and the Respiratory Panel 5-Plex test.**

The Partner is appointed by Genomtec S.A. to help with identification and qualification of new local business prospects and opportunities for the Genomtec® ID platform. The company will assist in selecting partners for obtaining market authorization in Taiwan and facilitating access to the Taiwanese market with Genomtec products.

The Partner is an innovative Polish – Taiwanese - Japanese biotechnology company specializing in the “go-to-market strategy” for medical diagnostics and nutraceuticals, specifically in the East Asian market. Their achievements are renowned internationally via many accolades and based on a close cooperation with the well-established Japanese and Taiwanese suppliers and experts in the biotechnology segment.

*"We are thrilled for this opportunity to expand in Taiwan through this partnership. Our Partner will be invaluable in both enhancing our ability to source and qualify potential business partners willing to enter into commercial agreements pertaining to sales and distribution of our products in Taiwan and representing the Genomtec brand in the local industry meetings, trade fairs, conferences. Being able to introduce such a rapid portable point-of-care diagnostics technology in the Taiwanese market is in line with our expansion strategy and we are excited to welcome our Partner onboard" said Charudutt Shah, Chief Business Officer at Genomtec S.A.*

On June 8, 2022, Genomtec S.A. announced obtaining the CE-IVD mark for its flagship solution, the Genomtec® ID Respiratory Panel 5-Plex (RP5-PLEX). It is the only diagnostic panel of its kind currently available in the European Union that simultaneously examines presence of the most relevant pathogens causing respiratory tract infections in the same test. The Genomtec® ID RP5-PLEX panel detects Influenza A/ B viruses, RSV (Respiratory Syncytial Virus), SARS-CoV-2, and bacteria causing atypical pneumoniae, i.e., *Mycoplasma pneumoniae* and *Chlamydomphila pneumoniae*. The Genomtec® ID Analyzer that orchestrates genetic analysis of loaded patient's sample onto the microfluidic reaction card (RP5-PLEX panel), is one of the smallest portable POCT genetic testing devices in the world.



####

**Additional information at:**

Genomtec S.A.  
Anna Bućko  
+48 881 204 105  
a.bucko@genomtec.com

**About Genomtec:**

Genomtec is an innovative medical technology company dedicated to the development and commercialization of a mobile molecular diagnostics platform for detection of various infectious diseases, and also rapid laboratory diagnostic tests used, among others, in the detection of COVID-19 disease caused by the SARS-CoV-2 virus.

The company's flagship project is the Genomtec ID mobile IVD platform. The analyser is uniquely placed among Point-Of-Care (POC) products worldwide. It will allow for a quick and precise clinical molecular analysis outside the standard laboratory setting, without the need to involve qualified laboratory personnel. The system uses microfluidic technology and the proprietary, patent protected SNAAT® isothermal technology. Appropriate design of the system enables the process to be carried out in record time, with the diagnostic parameters equal to, and in some cases exceeding, the quality of PCR laboratory tests.

The development and manufacturing process is executed in close cooperation with international CMO (Contract Manufacturing Organization) companies.

Genomtec was founded in 2016 and it headquartered in Wrocław.

More information at: [www.genomtec.com](http://www.genomtec.com)